Study summary
Vandetanib did not clearly slow iodine-resistant thyroid cancer
10.0 vs 5.7months before the cancer grew, vandetanib vs placebo, not a significant difference
What was tested
Vandetanib, a targeted pill, against placebo as the first drug treatment for advanced thyroid cancer that no longer responds to radioactive iodine.
What they found
- The time before the cancer grew was 10.0 months with vandetanib and 5.7 with placebo, which was not a statistically significant difference.
- Overall survival was not different.
- Serious side effects occurred in 55.6% on vandetanib and 25.4% on placebo.
What it means
Vandetanib is not an option for this form of thyroid cancer. It remains used for medullary thyroid cancer, a different type.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.